Jeffrey A Tornheim1, Kelly E Dooley2. 1. Division of Infectious Diseases. 2. Division of Clinical Pharmacology & Infectious Diseases, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: In the past few years, tuberculosis (TB) has overtaken HIV as the infectious disease with the highest global mortality. Successful management of this syndemic will require improved diagnostic tests, shorter preventive therapies, and more effective treatments, particularly in light of drug-resistant TB. RECENT FINDINGS: Results from several major studies have been published or presented recently, including the development of a more sensitive rapid, molecular assay for TB; several new symptom-based screening tools; use of a 1-month regimen for TB prevention; the results of early vs. delayed TB preventive therapy for pregnant women; newer drugs and regimens for multidrug-resistant tuberculosis; and pharmacokinetic, safety, and efficacy studies of new HIV drugs in combination with TB treatment. We reviewed each of these topic areas and summarize relevant findings for the management of TB and HIV co-infection. SUMMARY: Moving forward, as new treatment regimes for HIV or TB are developed, consideration of the HIV-TB co-infected patient must figure prominently, both when determining the diagnostic tests employed and to assess properly the drug-drug and drug-disease interactions that influence dosing, safety, and response.
PURPOSE OF REVIEW: In the past few years, tuberculosis (TB) has overtaken HIV as the infectious disease with the highest global mortality. Successful management of this syndemic will require improved diagnostic tests, shorter preventive therapies, and more effective treatments, particularly in light of drug-resistant TB. RECENT FINDINGS: Results from several major studies have been published or presented recently, including the development of a more sensitive rapid, molecular assay for TB; several new symptom-based screening tools; use of a 1-month regimen for TB prevention; the results of early vs. delayed TB preventive therapy for pregnant women; newer drugs and regimens for multidrug-resistant tuberculosis; and pharmacokinetic, safety, and efficacy studies of new HIV drugs in combination with TB treatment. We reviewed each of these topic areas and summarize relevant findings for the management of TB and HIV co-infection. SUMMARY: Moving forward, as new treatment regimes for HIV or TB are developed, consideration of the HIV-TB co-infectedpatient must figure prominently, both when determining the diagnostic tests employed and to assess properly the drug-drug and drug-disease interactions that influence dosing, safety, and response.
Authors: Amita Gupta; Michael D Hughes; Anthony J Garcia-Prats; Katherine McIntire; Anneke C Hesseling Journal: PLoS Med Date: 2019-08-15 Impact factor: 11.069
Authors: Christian Lienhardt; Andrew Nunn; Richard Chaisson; Andrew A Vernon; Matteo Zignol; Payam Nahid; Eric Delaporte; Tereza Kasaeva Journal: PLoS Med Date: 2020-02-27 Impact factor: 11.069
Authors: Leonn Mendes Soares Pereira; Eliane Dos Santos França; Iran Barros Costa; Erika Vanessa Oliveira Jorge; Patrícia Jeanne de Souza Mendonça Mattos; Amaury Bentes Cunha Freire; Francisco Lúzio de Paula Ramos; Talita Antonia Furtado Monteiro; Olinda Macedo; Rita Catarina Medeiros Sousa; Eduardo José Melo Dos Santos; Felipe Bonfim Freitas; Igor Brasil Costa; Antonio Carlos Rosário Vallinoto Journal: Front Immunol Date: 2022-03-16 Impact factor: 7.561
Authors: Brittney J van de Water; Isabel Fulcher; Suretha Cilliers; Nadishani Meyer; Michael Wilson; Catherine Young; Ben Gaunt; Karl le Roux Journal: PLoS One Date: 2022-04-05 Impact factor: 3.752
Authors: Matthew B Huante; Tais B Saito; Rebecca J Nusbaum; Kubra F Naqvi; Sadhana Chauhan; Robert L Hunter; Jeffrey K Actor; Jai S Rudra; Mark A Endsley; Joshua G Lisinicchia; Benjamin B Gelman; Janice J Endsley Journal: Front Cell Infect Microbiol Date: 2020-04-16 Impact factor: 5.293